Literature DB >> 6966296

OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

J P Van Wauwe, J R De Mey, J G Goossens.   

Abstract

OKT3, a monoclonal anti-human T cell antibody (IgG2), was found to induce DNA synthesis in human peripheral lymphocyte cultures. OKT3 induced maximal mitogenesis at a concentration of 10 to 20 ng/ml and was about 20-fold more potent than PHA as a mitogen. No high-dose inhibition of thymidine incorporation was noticed at concentrations up to 2.5 microgram OKT3/ml. The monovalent Fab fragment of OKT3 was also mitogenic but about 100 times less potent than the parent IgG. OKT3 appeared to be a T lymphocyte mitogen as only sheep red blood cell rosetting lymphocytes were responsive. Quantitative studies on the binding of 125I-labeled Fab fragment of OKT3 to human lymphocytes showed an average of 5.1 x 10(4) receptor sites/cell with an association of about 10(8) M-1 at 37 degrees C, with no heterogeneity of the cell binding sites. These data suggest a strong interaction of the monoclonal OKT3 with a limited number of identical T cell membrane receptors. As this interaction can trigger mitogenesis, the cell membrane determinant recognized by OKT3 could be described as a "T cell stimulation receptor." The mitogenecity of the lymphocytes is not solely dependent on cross-linking of these receptors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6966296

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  159 in total

1.  Pleiotropic contributions of phospholipase C-gamma1 (PLC-gamma1) to T-cell antigen receptor-mediated signaling: reconstitution studies of a PLC-gamma1-deficient Jurkat T-cell line.

Authors:  B J Irvin; B L Williams; A E Nilson; H O Maynor; R T Abraham
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  The antigen receptors on mature and immature T lymphocytes are coupled to phosphatidylcholine-specific phospholipase D activation.

Authors:  P A Reid; S D Gardner; D M Williams; M M Harnett
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

3.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Authors:  Gregory L Moore; Cristina Bautista; Erik Pong; Duc-Hanh T Nguyen; Jonathan Jacinto; Araz Eivazi; Umesh S Muchhal; Sher Karki; Seung Y Chu; Greg A Lazar
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

4.  Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.

Authors:  A Aruffo; B Seed
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Humanizing animal models: a key to autoimmune diabetes treatment.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Sci Transl Med       Date:  2011-02-02       Impact factor: 17.956

6.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Decreased proliferative activity associated with activation markers in patients with alcoholic liver cirrhosis.

Authors:  J Devière; C Denys; L Schandene; F Romasco; M Adler; J Wybran; E Dupont
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

8.  Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb.

Authors:  R A Janssen; A A Heijn; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

9.  Selective activation of antigen-experienced T cells by anti-CD3 constrained on nanoparticles.

Authors:  Ying-Chun Lo; Michael A Edidin; Jonathan D Powell
Journal:  J Immunol       Date:  2013-10-04       Impact factor: 5.422

Review 10.  Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis.

Authors:  J W Kreider; G L Bartlett; B L Butkiewicz
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.